Oncoletter Interviews in cooperation with VJHEMONC

 

Christian Buske:

Chemotherapy-free approaches in CLL, follicular lymphoma and DLBCL

2:31

Susan O’Brien:

Debate on the best first-line treatment for unmutated CLL: opinions from across the Atlantic

3:57

Brad Kahl:

ADCT-402 – a drug to watch

2:48

Sarah Huet:

Clinicogenetic risk models to predict outcome of follicular lymphoma patients

1:26

Won Seog Kim:

An overview on NK/T-cell lymphoma treatment

1:58

Won Seog Kim:

Biosimilars: Making biological agents availble worldwide

1:02

Ulrich Jager:

Diffuse large B-cell lymphoma lymphoma: Finding the best partner for durvalumab

2:49

Ulrich Jager: 

Exploring and consolidating the CLL world

1:02

Ulrich Jager: 

The current status of CLL treatment

3:26

Timothy Illdge:

The explosion of immuno-oncology

1:18

Timothy Illdge:

Combining radiotherapy and the immune system in lymphomas

2:49

Sattva Neelapu:

The pivotal ZUMA-1 trial for NHL

4:19

Graham Collins:

Personalising treatment to the biology of the NHL patient

2:38

Franco Cavalli:

The value of the ICML and highlights from the 2017 Annual Congress

2:19

Franco Cavalli:

What we can look forward to in the world of non-Hodgkin lymphoma

2:31

Bouthaina Dabaja:

Proton and photon therapy in managing hematological malignancies

3:15

Andrew Davies:

Key therapeutic advances in follicular lymphoma

4:02

Timothy Illdge:

Shifting the focus in lymphoma treatment

2:31

Sarah Huet:

Using models to predict progression in follicular lymphoma

1:01

Martin Fey:

The real cost of hematological cancer care explained

3:36

David Hodgson:

Reducing the risk of secondary malignancies in lymphoma

3:45

David Maloney:

Have novel drugs made stem cell transplantation obsolete?

1:13

David Maloney:

Immunotherapy highlights from ICML 2017

2:27

Christian Buske:

Comparing the efficacy and safety of CT-P10 to rituximab in advanced stages follicular lymphoma

2:53

Michael Wang:

A novel WINDOW of opportunity for young mantle cell lymphoma patients

2:23

Martine Bagot:

Escalating doses and improving outcomes in cutaneous T-cell lymphomas

1:24

George Follows:

Copanlisib produces promising results in relapsed/refractory follicular lymphoma

2:07

Christian Buske:

BGB-3111 and ibrutinib for Waldenström’s macroglobulinemia

2:48

Barbara Eichhorst:

Highlights from ICML 2017: The CLL2-BAG study

3:22
2:06
3:22